6 Best Peptides for Asthma

What to Know Before Choosing a Peptide for Asthma

Asthma is a chronic inflammatory airway condition, and people researching peptides for it are typically looking beyond the standard monoclonal antibody biologics. They want to understand the compounds being discussed in research communities, biohacking forums, and early clinical work. This guide is built around that search.

A peptide earns a slot here because people use it for asthma, or are actively discussing using it. That is the whole test. FDA-approved compounds qualify. So do compounds available through telehealth platforms, research-chemical channels, and the Eastern European clinical tradition. Evidence strength is stated honestly for each compound rather than used as a filter for inclusion. A compound with only community-reported use still belongs here, with its thin evidence described plainly. Quietly leaving out a widely-discussed compound because its trial data is limited would make this guide less useful than a basic forum search.

The entries are numbered by how prominently each compound appears in research and real-world use. That order is a spine for the list, not a verdict. It is not a recommendation of one compound over another for any specific person. A compound placed later here may be exactly the right starting point for someone, depending on their asthma phenotype, their immune picture, and what they are already using. The comparison table and FAQ are designed to help you see those distinctions clearly.

One broader point worth carrying through the whole article: none of these peptides appear in current GINA treatment guidelines, and none of them replace standard asthma care. Several are early-stage research tools. Others have decades of human data behind them for respiratory conditions adjacent to asthma rather than asthma itself. That honest framing is built into every entry below.

1. VIP: The Endogenous Bronchodilator with Analog Clinical Data

Vasoactive Intestinal Peptide is a 28-amino acid neuropeptide the body actually produces and releases from inhibitory nerve fibers in the lungs. It is not a foreign compound. It is part of the airway's own relaxation machinery, the primary endogenous bronchodilator from what physiologists call the non-adrenergic, non-cholinergic nervous system. The reason it leads this list is that the clinical evidence for its mechanism in asthma, and for a close analog, is more developed than anything else in the experimental peptide field for this condition.

VIP works by binding to VPAC1 and VPAC2 receptors on airway smooth muscle cells. When those receptors are activated, they trigger an increase in cyclic AMP inside the cell. That is the same signaling molecule beta-2 agonist inhalers use. That rise in cyclic AMP causes the smooth muscle to relax and the airway to open. Beyond the bronchodilatory effect, VIP also reduces inflammatory signaling across several pathways: it dials down the release of pro-inflammatory cytokines, modulates the activity of mast cells and T cells, inhibits histamine release, and suppresses NF-kB (a master switch controlling which inflammatory genes turn on).

The clinical finding that put VIP analogs on the map for asthma researchers came from work on a selective VPAC2 receptor agonist called Ro 25-1553. In human asthma patients, that compound delivered via inhalation produced bronchodilation comparable to formoterol, a standard beta-2 agonist clinicians prescribe daily. That is a meaningful benchmark. Researchers have also observed that VIP levels are lower in the lungs of asthmatic patients compared to healthy controls, which suggests VIP deficiency plays a role in the condition rather than simply being a pharmacological curiosity.

The limitation with native VIP is its half-life. It is broken down quickly by enzymes in the blood and airway tissue, which makes sustained bronchodilation from a single administration difficult. That is why research has shifted toward long-acting VIP analogs and stable VPAC2-selective compounds rather than the peptide itself. Native VIP is available as a research peptide, but no approved formulation for human asthma treatment exists anywhere. The strong mechanistic rationale and the analog clinical data make VIP the most evidence-grounded compound on this list for airway-focused use, even though it remains an experimental tool rather than a treatment option.

2. Thymosin Alpha-1: Immune Modulation for Virus-Triggered Asthma

Thymosin Alpha-1 is a 28-amino acid peptide derived from the thymus gland. A 2022 meta-analysis covering 39 randomized controlled trials and more than 3,300 patients established it as the compound with the deepest human clinical dataset of any on this list. The catch is that those trials were not primarily about asthma. They covered respiratory infections, COPD, COVID-19, hepatitis B and C, and cystic fibrosis. The asthma case rests on a combination of mechanism and adjacent evidence rather than a dedicated trial with asthma control as the primary endpoint.

The mechanism that makes Thymosin Alpha-1 interesting for asthma is its effect on the Th1 to Th2 immune balance. Allergic and eosinophilic asthma is largely a Th2-dominant condition, meaning the immune system is skewed toward the branch of activity that produces allergic inflammation, eosinophil recruitment, and elevated IgE. Thymosin Alpha-1 strengthens Th1 immune responses by enhancing T-cell maturation, boosting interferon-alpha and interferon-gamma production, and activating dendritic cells. Think of Th1 and Th2 as two sides of a seesaw: when one is overactive, the other tends to be suppressed. Thymosin Alpha-1's job, broadly, is to push weight back toward the Th1 side, which in theory could reduce the allergic inflammation driving asthma symptoms, though this has not been tested in a controlled asthma trial.

The more concrete use case, and the one that appears most consistently in community reports, is reducing the frequency and severity of viral upper respiratory infections. Viral triggers are one of the leading causes of asthma exacerbations. If Thymosin Alpha-1 reduces how often someone contracts a respiratory illness and how hard it hits, there is a plausible downstream benefit to asthma control even without a direct bronchodilatory effect. Users on peptide forums describe it helping with seasonal allergies, sinus problems, and the frequency of respiratory illnesses generally, though no community data specifically links it to improved lung function or better asthma attack frequency.

Thymosin Alpha-1 is commercially available as Zadaxin, a pharmaceutical-grade formulation approved in China, Italy, and several other countries for hepatitis and immune support. In the United States it is a research peptide without FDA approval for any indication. The safety profile from the clinical trial database is reassuring, with mild injection site reactions and occasional transient low-grade fever being the most commonly reported effects and no major adverse events at the standard research protocol. Around 20 to 30 percent of users report no noticeable benefit, a non-response pattern worth knowing before committing to a course.

3. GLP-1 Receptor Agonists: The Off-Label Class with the Strongest Real-World Reports

GLP-1 receptor agonists are synthetic peptide hormones. Compounds like semaglutide and tirzepatide were developed for type 2 diabetes and obesity and are now generating some of the most striking community reports of asthma improvement in the peptide research space. The biology gives those reports a plausible foundation. GLP-1 receptors are expressed in airway smooth muscle, and when activated they trigger the same cyclic AMP pathway that VIP and beta-2 agonists use, producing smooth muscle relaxation and airway opening. Beyond that direct bronchorelaxant effect, GLP-1 agonists stabilize mast cells, reducing the release of histamine and other inflammatory mediators central to allergic asthma. They also reduce serum periostin, a biomarker closely tied to airway inflammation and structural remodeling.

The human data is more developed here than for most compounds on this list, though none of it targets asthma as a primary endpoint. A Phase 2 randomized controlled trial registered on ClinicalTrials.gov under the identifier NCT05254314 is testing semaglutide in adults with obesity-related asthma using standardized asthma control questionnaire scoring as its primary measure. Retrospective studies have found that people using GLP-1 agonists for diabetes or obesity had significantly lower rates of asthma-related hospitalizations compared to people using a different diabetes drug class. A 2022 retrospective analysis published in a peer-reviewed respiratory pharmacology journal found GLP-1 receptor agonist users experienced roughly 10.7 asthma-related hospitalizations per 1,000 person-years, against 20.3 per 1,000 person-years for those using DPP-IV inhibitors instead. Liraglutide and semaglutide have also been shown in clinical studies to reduce periostin in adult asthmatics, which points toward a real effect on airway biology rather than symptom masking.

The community reports are where this class stands out. People on asthma forums and GLP-1 user communities describe coughs resolving within days of restarting their medication, going a full year without a flare, stopping their daily inhaled corticosteroid after several months, and getting through COVID infections without needing oral steroids for the first time. These are not small claims. They also come with the honest caveat that individual results vary considerably, and a meaningful share of users report no respiratory benefit.

GLP-1 agonists are FDA-approved for their primary indications, which means the legal and safety framework is different from the research peptides elsewhere on this list. The side effect profile is well-established, primarily gastrointestinal effects during dose escalation. The asthma use is off-label, and no asthma-specific protocol has been established. The investigational compound brenipatide, which works on both GLP-1 and GIP receptors, is in Phase 3 trials with asthma as a target indication, making this class worth following over the next several years.

4. Selank: Preclinical Evidence for Airway Hyperreactivity and Th2 Suppression

Selank is a synthetic heptapeptide based on the immune peptide tuftsin. It is best known in the peptide research community as an anxiolytic and nootropic compound, but it has a separate body of preclinical work specifically in asthma models that earns it a place here. No human trial data exists for Selank in asthma as of 2026. What has been published comes from mouse models using ovalbumin sensitization, the standard preclinical setup for studying allergic asthma.

In those animal studies, a 2019 investigation found Selank reduced airway hyperreactivity by roughly 22 to 28 percent compared to unsensitized controls. It also lowered eosinophil counts in airway tissue and reduced levels of IL-5 and IL-13, two cytokines that drive the type 2 inflammatory cascade in allergic asthma. IL-5 is the primary signal that keeps eosinophils alive and recruits them to the airways; IL-13 drives mucus overproduction and smooth muscle contraction. The mechanism behind those reductions runs through dampening of airway nerve signals, specifically tonic inhibition of vagal nerve afferents via GABA receptors, the same receptor system that regulates inhibitory nerve activity throughout the body. That means Selank reaches its anti-asthmatic effect through a genuinely different route from the other compounds here, representing a distinct angle on asthma pathology rather than a duplicate of the other entries.

Because all of this evidence comes from animal models, the translation to human asthma is genuinely uncertain. Selank users in peptide communities occasionally mention reduced nasal congestion and inflammation, but there is no body of user-reported data that specifically addresses asthma symptom control in any systematic way. It is included here because the mechanistic rationale is real and distinct, and it is relevant for anyone tracking the research landscape. The evidence is preclinical rather than clinical.

5. Chonluten: The Khavinson Bronchopulmonary Bioregulator

Chonluten is a tripeptide bioregulator developed as part of a research program at the St. Petersburg Institute of Bioregulation and Gerontology under Professor Vladimir Khavinson. The Khavinson peptide bioregulators are short peptides designed to act on specific tissues by interacting with DNA and influencing protein synthesis in a tissue-targeted way. Chonluten is the one aimed at bronchopulmonary tissue, with the proposed function of normalizing cellular activity in the bronchi and lungs, supporting mucosal membrane integrity, and reducing inflammatory signaling in the airway epithelium.

The research behind Chonluten sits almost entirely in the Russian and Eastern European scientific literature. The underlying theory of peptide bioregulation has a real scientific basis, since short regulatory peptides do interact with gene expression machinery, but the specific clinical evidence for Chonluten in asthma is limited by Western publication standards. Available work is largely observational or small-scale, and Chonluten does not appear in major Western clinical trial registries for asthma. It is not FDA-approved and is classified as a research peptide in most Western countries, though it carries a longer history of use in Russia and Eastern Europe.

In practice, Chonluten appears in the respiratory health sections of peptide bioregulator protocols and in discussions among users interested in the Khavinson system. The rationale for asthma centers on bronchopulmonary tissue restoration, mucous membrane support, and reduction of chronic airway inflammation rather than acute bronchodilation. It is not a rescue compound and is not described as fast-acting. No human clinical trial data has been published for Chonluten in asthma in any Western registry as of 2026. The evidence here is primarily observational and community-reported, drawn from a tradition of use rather than controlled research.

6. Bronchogen: The Oral Counterpart for Bronchial Epithelial Support

Bronchogen is a closely related tetrapeptide bioregulator from the same Khavinson research program as Chonluten, sharing the bronchopulmonary tissue target but differing in amino acid sequence. Where Chonluten is a tripeptide, Bronchogen is a tetrapeptide, and both are built on the same framework of short regulatory peptides acting on tissue-specific gene expression to normalize cell function, reduce inflammation, and support structural repair. The practical distinction most often raised in community discussions is that Bronchogen is more commonly available in oral capsule form, which matters for people who prefer non-injectable delivery.

The proposed mechanism for Bronchogen in asthma follows the same reasoning as Chonluten: normalizing the metabolism of bronchial epithelial cells, reducing excessive inflammation in the respiratory tract, supporting the repair and regeneration of airway tissue, and potentially reducing the frequency and severity of exacerbations over time. Neither compound is described as a fast-acting bronchodilator. The intended role is chronic support of bronchopulmonary tissue health rather than acute symptom relief, which places them in a different category from VIP or GLP-1 agonists mechanistically.

The evidence situation for Bronchogen closely mirrors Chonluten. The research base is primarily Russian, predominantly early-stage, and not well-represented in peer-reviewed Western literature or clinical trial registries. Community use in biohacking and longevity circles tends to treat Chonluten and Bronchogen as a complementary pair within broader Khavinson protocols, sometimes used together for respiratory support. Bronchogen is discussed anecdotally for asthma and chronic bronchial conditions, but no clinical trial with asthma as a primary endpoint has been published in accessible Western databases as of 2026. It is a research peptide in the United States and most Western countries.

How These Peptides Compare

Frequently Asked Questions

Are any peptides FDA-approved for asthma?

No peptide is currently FDA-approved specifically for asthma. The FDA-approved biologics for asthma, including dupilumab, tezepelumab, mepolizumab, and others, are monoclonal antibodies, large proteins that are structurally distinct from the short peptide compounds covered here. GLP-1 receptor agonists like semaglutide are FDA-approved for diabetes and weight loss, not asthma, so any respiratory benefit from those compounds is currently off-label use only.

How does the peptide approach to asthma differ from standard biologics?

Standard asthma biologics are monoclonal antibodies that block specific cytokines or receptors, such as IL-4, IL-5, or TSLP, that drive allergic inflammation. The peptides covered in this guide work through different mechanisms: some relax airway smooth muscle directly, some modulate the immune system more broadly, and some are proposed to support bronchopulmonary tissue health over time. The peptide approach is largely experimental compared to approved biologics, which have completed large Phase 3 trials with defined patient populations where their efficacy is established.

Can peptides be used alongside existing asthma medications?

This is a question best answered by a physician who knows your specific medication list and asthma phenotype. Some compounds, like Thymosin Alpha-1, have been used alongside standard treatments in clinical settings for other respiratory conditions. Others, like VIP analogs, exist only in research contexts at present. The interaction between most of these peptides and inhaled corticosteroids or beta-2 agonists has not been formally studied, which is another reason a qualified healthcare provider needs to be part of any decision to add a peptide protocol to an existing asthma regimen.

Do community reports link any of these peptides to stopping asthma attacks?

GLP-1 receptor agonists generate the most striking community reports for respiratory benefit, with some users describing extended periods without flares and stopping their daily inhalers after months of consistent use. Thymosin Alpha-1 is reported to reduce the frequency of respiratory infections that trigger exacerbations, though users do not describe it stopping attacks directly. For the other compounds on this list, user-reported data specific to asthma attack frequency is sparse, and none of them should ever be treated as a substitute for a rescue inhaler during an acute episode.

This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. MyPeptidePal is not a medical provider. Always consult a qualified healthcare professional before starting, modifying, or stopping any health protocol, supplement regimen, or therapeutic intervention.

Sources

The information in this guide is drawn from the MyPeptidePal knowledge base, which brings together published research, clinical data, and documented real-world use of peptides for asthma in one place.